Virttu Biologics Limited, a UK biotechnology company, issued this press release in late August 2013, “Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR(R) Study in Mesothelioma.”
From that article we get these four (4) facts:
- SEPREHVIR (HSV1716) is a variant of Herpes Simplex Virus 1 that has been engineered to kill cancer cells while leaving normal cells unharmed.
- Malignant pleural mesothelioma (MPM) has a long latency (30-60 years from occupational exposure) and Virttu estimates that around 9500 new cases of MPM occur each year in the US and the larger EU member states.
- MPM survival is influenced by disease stage patient age and overall health and management is largely palliative and multimodal combining surgery radiotherapy and chemotherapy.
- The primary objective of the study is to determine the safety and tolerability of SEPREHVIR when given both as single and repeat intrapleural doses in patients with inoperable malignant pleural mesothelioma (MPM); a form of lung cancer that is almost exclusively caused by occupational exposure to certain types of asbestos.
For further information on the Phase I/II SEPREHVIR(R) study concerning a possible new treatment for patients diagnosed with pleural mesothelioma see this page, “A study looking at HSV1716 to treat mesothelioma”, at the Cancer Research UK web site.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.